Vor Biopharma, Inc. VOR 深 滬
交易中 01-28 11:13:27 美东时间
14.10
-0.660
-4.47%
華盛通- 最 高14.75
- 今 開14.50
- 成交量 27.64万股
- 最 低 13.8308
- 昨 收 14.76
- 總市值 3.09亿
- 52周最高 65.80
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 2.622
- 委 比 -99.11%
- 總股本 2191.06万
- 歷史最高 1272.40
- 量 比 1.49
- 振 幅 6.23%
- 歷史最低 2.622
- 每 手 1
- 風險率 13.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vor Biopharma to Highlight Telitacicept at JPM Conference
Vor Biopharma ( ($VOR) ) has provided an update. Vor Biopharma announced that i...
01-12 23:18
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Citigroup Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $50
Citigroup analyst Geoff Meacham initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Buy rating and announces Price Target of $50.
01-09 20:48
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma announced the appointments of Andrew Levin, M.D., Ph.D., and Wouter Joustra to its Board of Directors following a $150M PIPE financing. Both investors bring extensive experience in life sciences and strategic oversight. This addition is aimed at advancing Vor Bio's global Phase 3 programs for telitacicept in treating autoimmune diseases.
2025-12-23 21:01
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
JP Morgan Maintains Overweight on Vor Biopharma, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Vor Biopharma (NASDAQ:VOR) with a Overweight and lowers the price target from $43 to $40.
2025-12-20 00:25
TD Cowen Initiates Coverage On Vor Biopharma with Buy Rating
TD Cowen analyst Yaron Werber initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Buy rating.
2025-12-17 23:20
Vor Bio announces $150M private placement
Vor Bio (NASDAQ:VOR) announced on Monday that it has entered into a securities purchase agreement to sell 13.87M shares of its common stock at a price of $10.81 per share in a private placement. The c...
2025-12-15 21:45
Vor Bio Announces $150M Private Placement Of Common Stock At $10.81/Shr
Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its
2025-12-15 21:02
美股牛股 | SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%
SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%，财报收入大增超预期；GEMI大涨32%，公司获合约市场牌照进军预测市场>>
2025-12-12 16:17
